Last reviewed 2026-06-10 · How we verify

metastatic neuroendocrine tumors — Treatment Landscape & Competitive Intelligence

metastatic neuroendocrine tumors (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating metastatic neuroendocrine tumors, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Sun Pharm Inds Inc · 1 drug in metastatic neuroendocrine tumors

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in metastatic neuroendocrine tumors:

• metastatic neuroendocrine tumors treatment updates — RSS
• metastatic neuroendocrine tumors treatment updates — Atom
• metastatic neuroendocrine tumors treatment updates — JSON

Cite this brief

Drug Landscape (2026). metastatic neuroendocrine tumors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-neuroendocrine-tumors. Accessed 2026-06-10.

Related

• metastatic neuroendocrine tumors full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing